IL5 and eosinophil disorder: IL-5 has been identified as a therapeutic target for eosinophilic diseases and several monoclonal antibodies have been approved for clinical use in the treatment of severe asthma, for example, mepolizumab and reslizumab targeting IL-5, and benralizumab targeting the IL-5 receptor (23, 24).